Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.

Clin Transplant 2018 01 5;32(1). Epub 2018 Jan 5.

Abteilung für Nephrologie, Universitätsklinikum Regensburg, Regensburg, Germany.

This study assessed adherence to prolonged-release tacrolimus (PR-T)-based immunosuppression during routine maintenance of renal transplant recipients in Germany. Patients had received PR-T for ≥1 month at inclusion. Data were collected during four visits (V): baseline (V1), 6 (V2), 12 (V3), and 18 (V4) months. Composite primary endpoint: nonadherence at V4, defined as self-reported nonadherence on the Basel Assessment of Adherence with Immunosuppressive Medication Scale (BAASIS ), investigator-rated nonadherence, and/or V4 tacrolimus trough level outside a predefined range. Secondary endpoints: individual BAASIS items, incidence of rejection, kidney function, and safety. Overall, 153 adult kidney recipients (mean [standard deviation] time post-transplant 5.8 [4.6] years) were included. Nonadherence was high at V4 (67.7% [95% confidence interval 58.9%, 75.6%]). Medication-taking adherence was 86.9% and 91.3% at V1 and V4, respectively; adherence to timing of medication intake was 58.2% and 58.3%, with little evidence of missed doses/drug holidays. Investigators rated adherence "good" in 85.6% of patients (V4). Two (1.3%) patients had acute rejection episodes. Kidney function remained stable (mean creatinine clearance, V1: 62.1 mL/min; V4: 65.3 mL/min). Investigators rated effectiveness of PR-T as "very good"/"good" in 91.5% of patients. Most patients (94.7%) found PR-T dosing more convenient than immediate-release tacrolimus. PR-T was well tolerated with high medication persistence.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.13142DOI Listing
January 2018
36 Reads

Publication Analysis

Top Keywords

investigators rated
8
kidney function
8
prolonged-release tacrolimus
8
patients
6
adherence
5
677% [95%
4
[95% confidence
4
high 677%
4
nonadherence high
4
time post-transplant
4
post-transplant [46] years
4
[46] years included
4
included nonadherence
4
interval 589%
4
913% adherence
4
adherence timing
4
timing medication
4
medication intake
4
869% 913%
4
adherence 869%
4

References

(Supplied by CrossRef)
Nonadherence to immunosuppression: challenges and solutions
Moreso et al.
Transplant Res Risk Manag 2015

Similar Publications